Gene therapy to prevent HCC recurrence after LDLT for HCC
| Project/Area Number |
22791290
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 肝臓外科学 / 遺伝子治療 / IL-12 / 樹状細胞 / 免疫治療 / 肝細胞癌 / 肝移植 / 生体肝移植 |
|---|
| Research Abstract |
We found that the IL-12/DC combined immunotherapy exerted effective antitumor effects on the immunosuppressed host, resulting in significant suppression of growth of the subcutaneous established tumor and complete suppression of lung and liver metastasis, without rejection of a fully allogenic skin graft. These antitumor effects were dependent on both T cells and NK cells. Noteworthily, the combined intratumoral immunotherapy and tumor resection, that is to say" neoadjuvant immunotherapy", resulted in curative treatment of immunosuppressed mice for HCC, even when the mice were challenged with intravenous injection of HCC at the time of tumor resection.
|
Report
(3 results)
Research Products
(19 results)
